Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice.

Authors: Erpenbeck, VJ  Ziegert, M  Cavalet-Blanco, D  Martin, C  Baelder, R  Glaab, T  Braun, A  Steinhilber, W  Luettig, B  Uhlig, S  Hoymann, HG  Krug, N  Hohlfeld, JM 
Citation: Erpenbeck VJ, etal., Clin Exp Allergy. 2006 Jul;36(7):930-40.
Pubmed: (View Article at PubMed) PMID:16839409
DOI: Full-text: DOI:10.1111/j.1365-2222.2006.02524.x

BACKGROUND: The surfactant protein SP-D has been reported to reduce bronchial hyper-responsiveness, blood eosinophilia, and T-helper type 2 cytokines in models of allergic asthma. However, little is known about the functional effect of SP-D on the early airway response upon allergen inhalation, which is an important feature of this disease. OBJECTIVE: We investigated whether SP-D is able to reduce the immediate allergen-induced mediator release and the early bronchial obstruction in addition to its effects on airway inflammation and bronchial hyperresponsiveness in an Aspergillus fumigatus mouse asthma model. METHODS: A. fumigatus-sensitized mice were treated with a recombinant fragment of human SP-D or placebo. Lung functions were measured in orotracheally intubated, spontaneously breathing animals using body plethysmography. In addition, passively sensitized precision-cut lung slices (PCLS) were used to determine the effect of SP-D on allergen-induced histamine release. RESULTS: SP-D inhibited the allergen-induced early airway response and reduced airway hyperresponsiveness compared with placebo. Eosinophilia in bronchoalveolar lavage and lung tissue was reduced after SP-D treatment, possibly by reducing eotaxin levels in the lung. Furthermore, SP-D treatment reduced the allergen-induced histamine release from PCLS. CONCLUSION: These data suggest that SP-D not only reduces allergen-induced eosinophilic inflammation and airway hyperresponsiveness but also provides protection against early airway obstruction by inhibition of early mediator release.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 4143508
Created: 2010-09-27
Species: All species
Last Modified: 2010-09-27
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.